{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:30:12Z","timestamp":1791297012454,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":36,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642294228","type":"print"},{"value":"9783642294235","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-29423-5_10","type":"book-chapter","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T01:26:30Z","timestamp":1345685190000},"page":"239-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis"],"prefix":"10.1007","author":[{"given":"Sergio","family":"Leonardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,23]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker RC, Moliterno DJ, Jennings LK et al (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919\u2013928","journal-title":"Lancet"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330\u20132341","journal-title":"N Engl J Med"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1021\/jm800180e","volume":"51","author":"S Chackalamannil","year":"2008","unstructured":"Chackalamannil S, Wang Y, Greenlee WJ et al (2008) Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51:3061\u20133064","journal-title":"J Med Chem"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/01.ATV.0000319737.80976.26","volume":"28","author":"M Chintala","year":"2008","unstructured":"Chintala M, Vemulapalli S, Kurowski S, Sabin C, Reynolds D, Prevete K, Friedrichs G (2008) (2008) SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Atheroscler Thromb Vasc Biol 28:e32\u2013e149","journal-title":"Atheroscler Thromb Vasc Biol"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/ATVBAHA.110.203414","volume":"30","author":"M Chintala","year":"2010","unstructured":"Chintala M, Strony J, Yang B, Kurowski S, Li Q (2010) SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 30:2143\u20132149","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"11023","DOI":"10.1073\/pnas.96.20.11023","volume":"96","author":"SR Coughlin","year":"1999","unstructured":"Coughlin SR (1999) How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96:11023\u201311027","journal-title":"Proc Natl Acad Sci USA"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/35025229","volume":"407","author":"SR Coughlin","year":"2000","unstructured":"Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258\u2013264","journal-title":"Nature"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Dav\u00ec","year":"2007","unstructured":"Dav\u00ec G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482\u20132494","journal-title":"N Engl J Med"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH03-06-0391","volume":"91","author":"C Dubois","year":"2004","unstructured":"Dubois C, Steiner B, Meyer Reigner SC (2004) Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 91:733\u2013742","journal-title":"Thromb Haemost"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1053\/euhj.2000.3234","volume":"23","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, Weitz JI, Budaj A et al (2002) Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 23:1771\u20131779","journal-title":"Eur Heart J"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1124\/dmd.110.035493","volume":"39","author":"A Ghosal","year":"2011","unstructured":"Ghosal A, Lu X, Penner N et al (2011) Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos 39:30\u201338","journal-title":"Drug Metab Dispos"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5551\/jat.3038","volume":"17","author":"S Goto","year":"2010","unstructured":"Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P (2010a) Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 17:156\u2013164","journal-title":"J Atheroscler Thromb"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","volume":"31","author":"S Goto","year":"2010","unstructured":"Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL (2010b) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 31:2601\u20132613","journal-title":"Eur Heart J"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","volume":"121","author":"PA Gurbel","year":"2010","unstructured":"Gurbel PA, Tantry US (2010) Combination antithrombotic therapies. Circulation 121:569\u2013583","journal-title":"Circulation"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.1538-7836.2004.00783.x","volume":"2","author":"JR Hamilton","year":"2004","unstructured":"Hamilton JR, Cornelissen I, Coughlin SR (2004) Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2:1429\u20131435","journal-title":"J Thromb Haemost"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318\u20132329","journal-title":"N Engl J Med"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1172\/JCI6042","volume":"103","author":"ML Kahn","year":"1999","unstructured":"Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879\u2013887","journal-title":"J Clin Invest"},{"key":"10_CR18","first-page":"280","volume":"108","author":"M Kogushi","year":"2003","unstructured":"Kogushi M, Kobayashi H, Matsuoka T et al (2003) Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs. Circulation 108:280, Abstract","journal-title":"Circulation"},{"key":"10_CR19","unstructured":"Kogushi M, Yokohama H, Kitamura S et al (2007) Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. Presented at XXIst congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejphar.2011.01.058","volume":"657","author":"M Kogushi","year":"2011","unstructured":"Kogushi M, Matsuoka T, Kawata T et al (2011a) The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 657:131\u2013137","journal-title":"Eur J Pharmacol"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2011.05.034","volume":"666","author":"M Kogushi","year":"2011","unstructured":"Kogushi M, Matsuoka T, Kuramochi H et al (2011b) Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol 666:158\u2013164","journal-title":"Eur J Pharmacol"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"S Leonardi","year":"2010","unstructured":"Leonardi S, Rao SV, Harrington RA et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160:65\u201372","journal-title":"Am Heart J"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"68A","DOI":"10.1016\/S0735-1097(04)90284-7","volume":"43","author":"T Matsuoka","year":"2004","unstructured":"Matsuoka T, Kogushi M, Kawata T et al (2004) Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J Am Coll Cardiol 43:68A","journal-title":"J Am Coll Cardiol"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"335.e3","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Fox KA et al (2009) Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2\u00b0P)-TIMI 50 trial. Am Heart J 158:335.e3\u2013341.e3","journal-title":"Am Heart J"},{"issue":"15","key":"10_CR250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404\u20131413","journal-title":"N Engl J Med"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","volume":"123","author":"ML O\u2019Donoghue","year":"2011","unstructured":"O\u2019Donoghue ML, Bhatt DL, Wiviott SD et al (2011) Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes\/clinical perspective. Circulation 123:1843\u20131853","journal-title":"Circulation"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garc\u00eda Rodr\u00edguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373\u20132383","journal-title":"N Engl J Med"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","volume":"102","author":"VL Serebruany","year":"2009","unstructured":"Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL (2009) The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102:111\u2013119","journal-title":"Thromb Haemost"},{"issue":"4","key":"10_CR28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.09.005","volume":"1","author":"Y Shinohara","year":"2012","unstructured":"Shinohara Y, Goto S, Doi M, Jensen P (2012) Safety of the novel protease-activated receptor-1 antagonist Vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis 1(4):318\u201324","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","unstructured":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ahj.2009.07.001","volume":"158","author":"The TRACER Executive Steering C","year":"2009","unstructured":"The TRACER Executive Steering C (2009) The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER) trial: study design and rationale. Am Hear J 158:327\u2013334","journal-title":"Am Hear J"},{"issue":"1","key":"10_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366(1):20\u201333","journal-title":"N Engl J Med"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin L, Varenhorst C, James S et al (2008) Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21\u201330","journal-title":"Eur Heart J"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","volume":"123","author":"SD Wiviott","year":"2011","unstructured":"Wiviott SD, Flather MD, O\u2019Donoghue ML et al (2011) Randomized trial of atopaxar in the treatment of patients with coronary artery disease\/clinical perspective. Circulation 123:1854\u20131863","journal-title":"Circulation"}],"container-title":["Handbook of Experimental Pharmacology","Antiplatelet Agents"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-29423-5_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:50:55Z","timestamp":1558093855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-29423-5_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642294228","9783642294235"],"references-count":36,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-29423-5_10","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"23 July 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}